|
|
|
| Dec. 13, 2006 |
Amgen Announces $5 Billion Stock Repurchase Plan
|
| Dec. 11, 2006 |
Updated Interim Long-Term Follow-up Data Reported AMG 531 Dosed Once Weekly Increased and Sustained Platelet Counts in Patients with Immune Platelet Disorder
|
| Dec. 10, 2006 |
Final Phase 2 Data Continue to Show Promising Results after One Year of Aranesp(R) Treatment for Anemia in Patients with Myelodysplastic Syndromes (MDS)
|
| Dec. 9, 2006 |
Data Show Efficacy of Extended Dosing of Aranesp(R) in the Treatment of Chemotherapy-Induced Anemia
|
| Dec. 9, 2006 |
New Phase 2 Data Show Promise of Aranesp(R) Treatment for Anemia of Cancer
|
| Dec. 4, 2006 |
Amgen Responds to Reports About Use and Safety of EPOGEN and Aranesp in CKD Anemia Therapy
|
| Dec. 1, 2006 |
Amgen Names Yuji Orihara President, Amgen KK
|
| Nov. 29, 2006 |
Colorectal Patients Offered New Resource to Help Navigate Treatment Process
|
| Nov. 22, 2006 |
District Court Judge Denies Preliminary Injunction in Ortho v. Amgen Suit
|
| Nov. 20, 2006 |
Fashion Designer and Cancer Survivor Carmen Marc Valvo Offers Support
|
| Nov. 16, 2006 |
Amgen Launches ChemoCoach.com and ``My Cancer Coach'' Contest in Conjunction with Sponsorship of College Hoops Classic Benefiting Coaches vs. Cancer
|
| Nov. 13, 2006 |
Data Shows ENBREL Provides Sustained Clinical Improvements for People with Ankylosing Spondylitis for up to Three Years
|
| Nov. 12, 2006 |
ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy for up to Nine Years in Patients with Moderate-to-Severe Rheumatoid Arthritis
|
| Nov. 4, 2006 |
AMG 706 Shows Activity in Phase 2 Study of Patients with Advanced Imatinib-Resistant Gastrointestinal Stromal Tumors
|
| Nov. 2, 2006 |
Nominations Open for the Amgen Award for Science Teaching Excellence
|
| Oct. 24, 2006 |
Amgen Completes Acquisition of Avidia
|
| Oct. 23, 2006 |
Amgen's Third Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 22 Percent to $1.04
|
| Oct. 20, 2006 |
U.S. District Court Denies Roche Motion to Dismiss Amgen Patent Infringement Lawsuit
|
| Oct. 19, 2006 |
Amgen Foundation Launches $25 Million Undergraduate Research Program
|
| Oct. 13, 2006 |
Amgen Receives Complete Response Letter for Extended Dosing of Aranesp(R) for Patients with Chronic Kidney Disease and Anemia
|
| Oct. 9, 2006 |
Amgen Announces Webcast of Third Quarter Financial Results
|
| Sep. 29, 2006 |
Amgen to Acquire Avidia, a Privately Held Biopharmaceutical Company in the San Francisco Bay Area
|
| Sep. 27, 2006 |
Amgen Introduces Comprehensive Financial Assistance Programs for Cancer Patients
|
| Sep. 27, 2006 |
FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer
|
| Sep. 20, 2006 |
Amgen Names Thomas Flanagan Senior Vice President and Chief Information Officer
|
| Sep. 19, 2006 |
Amgen Announces License Agreement with Yeda Research and Development Company Ltd.; License Agreement Accords Amgen Freedom to Operate Under '866 Patent
|
| Sep. 19, 2006 |
Amgen Presents Denosumab and Sclerostin Antibody Data at American Society for Bone and Mineral Research Annual Meeting; Data Suggest the Potential for Targeting the Key Proteins, RANK Ligand and Sclerostin, for Bone Loss Conditions
|
| Sep. 7, 2006 |
Amgen Launches Aranesp(R) (Darbepoetin Alfa) Prefilled SureClick(TM) Autoinjector for Treatment of Anemia Associated with Chemotherapy and Chronic Kidney Disease
|
| Aug. 3, 2006 |
Amgen Wins TKT Appeal
|
| Jul. 20, 2006 |
Amgen's Second Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 19 Percent to $1.05; GAAP Earnings Per Share of 1 Cent Reflects $1.1 Billion One-Time Write-Off of In-Process R&D Related to Abgenix Acquisition
|
| Jul. 18, 2006 |
Amgen Update on Presentation Materials for Webcast of Second Quarter Financial Results
|
| Jul. 16, 2006 |
Amgen Announces EVOLVE Trial(TM) To Investigate Impact of Sensipar(R)/Mimpara(R) (cinacalcet HCl) on Mortality and Cardiovascular Morbidity in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease Receiving Dialysis
|
| Jul. 11, 2006 |
Amgen Announces Termination of Poison Pill Effective July 31, 2006
|
| Jul. 7, 2006 |
ITC Judge Grants Summary Determination That Roche's Activities Are Covered by Clinical Trial Exemption
|
| Jul. 6, 2006 |
Amgen Announces Webcast of Second Quarter Financial Results
|
| Jun. 19, 2006 |
Final Results of Phase 2 Clinical Trial Program Suggest Treatment of Anemia with Aranesp(R) (Darbepoetin Alfa) May Decrease Risk of Hospitalization and All-Cause Mortality in Heart Failure Patients with Anemia, Based on a Prespecified Pooled Analysis
|
| Jun. 12, 2006 |
FDA Grants Priority Review of Panitumumab for Treatment of Patients with Metastatic Colorectal Cancer
|
| Jun. 4, 2006 |
Phase 2 Interim Data Show Denosumab Decreased Bone Turnover in Advanced Cancer Patients with Bone Metastases
|
| Jun. 3, 2006 |
Interim Data Suggest Potential Benefits of Aranesp(R) Dosed Every Three Weeks with Intravenous Iron for Chemotherapy-Induced Anemia; 94 Percent of Patients Achieved Target Hemoglobin Level
|
| Jun. 3, 2006 |
Interim Phase 2 Aranesp(R) Data Suggest Major Response after 27/28 Weeks of Treatment for Anemia in Patients with Myelodysplastic Syndromes (MDS)
|
| Jun. 3, 2006 |
New Interim Phase 2 Data Suggest the Antitumor Activity of Panitumumab in Metastatic Colorectal Cancer
|
| May. 31, 2006 |
Amgen Oncology Highlights Upcoming Data Presentations at the American Society of Clinical Oncology Annual Meeting; Clinical Data to be Presented on Four Investigational Targeted Cancer Therapies
|
| May. 18, 2006 |
Large Head-to-Head Study of Aranesp(R) Dosed Every Two Weeks versus Epoetin Alfa Dosed Weekly Published in the Journal of Clinical Oncology
|
| May. 9, 2006 |
ITC Accepts Amgen's Complaint to Investigate Roche's Importation of Peg-EPO
|
| Apr. 24, 2006 |
Alcon and Amgen Sign Collaboration Agreement to Develop and Commercialize Innovative Therapies in Ophthalmology
|
| Apr. 18, 2006 |
Amgen's First Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 26 Percent to 91 Cents; First Quarter 2006 GAAP Earnings Per Share Increased 22 Percent to 82 Cents
|
| Apr. 11, 2006 |
Amgen Files with ITC Against Roche's Importation of peg-EPO
|
| Apr. 10, 2006 |
2006 Recipients of Amgen Award for Science Teaching Excellence Announced; 19 Outstanding Science Teachers and Their Schools Recognized in Amgen Communities Across the U.S. and Puerto Rico
|
| Apr. 4, 2006 |
Amgen Announces Webcast of First Quarter Financial Results
|
| Apr. 3, 2006 |
Randomized Phase 3 Trial Shows Panitumumab Significantly Improved Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
|
| Apr. 3, 2006 |
Amgen Completes Acquisition of Abgenix; Acquisition Provides Amgen with Full Ownership of Panitumumab and Eliminates a Denosumab Royalty
|
| Mar. 30, 2006 |
Amgen and Abgenix Complete Biologics License Application for FDA Approval of Panitumumab
|
| Mar. 27, 2006 |
FDA Approves Extended Dosing of Aranesp(R) to Treat Chemotherapy-Induced Anemia; Every-Three-Week Dosing Can Provide Added Convenience, Potentially Reducing Number of Clinic Visits and Injections for Anemia Treatment
|
| Mar. 13, 2006 |
New Phase 2 Data Suggest Treatment of Anemia with Aranesp(R) (Darbepoetin Alfa) May Provide Clinical Benefits in Heart Failure Patients
|
| Feb. 26, 2006 |
Amgen Donates $1.1 Million to The Wellness Community as Part of of ``Breakaway from Cancer'' Initiative and Title Sponsorship of Amgen Tour of California
|
| Feb. 25, 2006 |
Hundreds of Local Residents Participate in Breakaway from Cancer Charity Ride to Benefit The Wellness Community; Bruce Jenner Kicks-off Twenty-Five Mile Ride That Coincides with Stage Six of Amgen Tour of California
|
| Feb. 22, 2006 |
Investigational Therapy Denosumab Increased Bone Mineral Density with Twice-Yearly Dosing; One Year Data Published in New England Journal of Medicine
|
| Feb. 14, 2006 |
Amgen Prices $5.0 Billion Convertible Senior Notes; Company to Purchase Approximately $3.0 Billion in Common Stock
|
| Feb. 13, 2006 |
Amgen to Offer $4.0 Billion Convertible Senior Notes; Company to Purchase Approximately $3.0 Billion in Common Stock
|
| Feb. 13, 2006 |
Amgen and Biovitrum Expand Existing License Agreement for Innovative Treatment of Type 2 Diabetes and Other Metabolic Disorders
|
| Feb. 2, 2006 |
Amgen Continues Manufacturing Expansion with Additional $1 Billion Investment in Puerto Rico
|
| Jan. 26, 2006 |
Amgen's Fourth Quarter 2005 Adjusted Earnings Per Share Increased 29 Percent to 75 Cents; Full Year 2005 Adjusted Earnings Per Share Increased 33 Percent to $3.20
|
| Jan. 26, 2006 |
Amgen and Genentech Sign License Agreements For Antibody Patents
|
| Jan. 24, 2006 |
Amgen to Make Significant Investment in Manufacturing, R&D and Commercial Operations Expansion
|
| Jan. 9, 2006 |
Amgen Announces Webcast of 2005 Fourth Quarter and Full Year Financial Results
|
